![3-[(Methylsulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide](https://static.cymitquimica.com/cas-image/352035-3-methylsulfonyl-amino-2-phenyl-n-1s-1-phenylpropyl-4-quinolinecarboxamide.png)
CAS: 941690-55-7 - 3-[(Methylsulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide
Formula:C26H25N3O3S
InChI:InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
InChI key:InChIKey=QYTBBBAHNIWFOD-NRFANRHFSA-N
SMILES:O=C(NC(C=1C=CC=CC1)CC)C=2C=3C=CC=CC3N=C(C=4C=CC=CC4)C2NS(=O)(=O)C
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | MLE-4901 REF: TR-M368765CAS: 941690-55-7 | - - - | 2,174.00 € | Mon 17 Jun 24 |
 | Pavinetant REF: 3D-RMB69055CAS: 941690-55-7 | Min. 95% | To inquire | Tue 18 Jun 24 |
 | Pavinetant REF: TM-T16114CAS: 941690-55-7 | 99.60% | 80.00 €~267.00 € | Tue 25 Jun 24 |
MLE-4901
Controlled ProductCAS:941690-55-7
Applications MLE-4901, is a neurokinin-3 receptor (NK3R) antagonist. References Li, Y. et al.: Xenobiotica. 2010 …
Formula:
C26H25N3O3S
Molecular weight:
459.56
Ref: TR-M368765
| 250mg | 2,174.00 € |
Estimated delivery in United States, on Monday 17 Jun 2024
Pavinetant
CAS:941690-55-7
Pavinetant is a drug that interacts with the neurokinin-1 receptor. It is being studied as …
Formula:
C26H25N3O3S
Purity:
Min. 95%
Molecular weight:
459.56 g/mol
Ref: 3D-RMB69055
| 1mg | To inquire | |
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Jun 2024
Pavinetant
CAS:941690-55-7
Pavinetant is a small molecule orally active and selective neurokinin-3 (NK3) receptor antagonist for the …
Formula:
C26H25N3O3S
Purity:
99.60%
Color and Shape:
Solid
Molecular weight:
459.56
Ref: TM-T16114
| 2mg | 102.00 € | |
| 5mg | 173.00 € | |
| 10mg | 267.00 € | |
| 1ml*10 (DMSO) | 171.00 € |
Estimated delivery in United States, on Tuesday 25 Jun 2024
